Phase 3 Trials of Lanabecestat in Alzheimer’s Patients Stopped for Lack of Efficacy, Eli Lilly and AstraZeneca Announce

Phase 3 Trials of Lanabecestat in Alzheimer’s Patients Stopped for Lack of Efficacy, Eli Lilly and AstraZeneca Announce
Eli Lilly and AstraZeneca announced that they are stopping two global Phase 3 trials of lanabecestat, an amyloid beta-targeting treatment candidate for Alzheimer's, because of an apparent lack of benefit. Safety was not of concern in either trial. The decision follows recommendations by an independent data monitoring committee, which concluded that both trials — the AMARANTH Phase 2/3 study (NCT02245737)  in early Alzheimer’s patients and the DAYBREAK-ALZ Phase 3 trial (
Subscribe or to access all post and page content.